Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new ...
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...
Dynavax Technologies’ (DVAX) Outperform Rating Reaffirmed at William Blair
Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...
Dynavax price target raised to $33 from $29 at Citizens JMP
Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...
Dynavax Technologies Full Year 2024 Earnings: EPS Misses Expectations
Full Year 2024 Results Key Financial Results Revenue: US$277.2m (up 19% from ...
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement ...
Business Wire4d
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NAS ...
JMP Securities Keeps Their Buy Rating on Dynavax (DVAX)
JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...
Dynavax Technologies: Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...
Morningstar4d
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical ...